ROCKET PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M |
| Operating expenses | $231.7M | $273.2M | $259.7M | $224.3M | $167.2M |
| Cash from operations | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M |
| Capital expenditure | $440,000 | $5.9M | $16.4M | $8.4M | $7.6M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M |
Shares outstanding 109.2M · Free float 78.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.